<abstract xmlns="http://www.w3.org/1999/xhtml">
<p>The spread of SARS-CoV-2 represented a global health crisis. On May 5, 2023, the chief of the World Health Organization (WHO) officially announced the end of COVID-19 as a global health emergency. Serological assays can identify previously infected SARS-CoV-2 individuals, even if they did not go for testing while acutely ill. The current study sought to detect antibodies directed against the nucleocapsid of SARS-CoV-2 (IgG against the SARS-CoV-2 N protein) in both vaccinated and unvaccinated COVID-19 individuals. Of the 100 participants, 53 and 47 were vaccinated and unvaccinated, respectively. The vaccination status of the cohort based on gender data indicates that 41 (41%) of all participants were vaccinated males, whereas 12 (12%) were vaccinated females. We found that 42 (42%) were unvaccinated males and 5 (5%) were unvaccinated females. Of 53 vaccinated subjects, 42 and 11 participants were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. Of 47 unvaccinated participants, 28 and 19 were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. The average of S/P “Sample/Positive control” percentages, which correlate to levels of IgG against SARS-CoV-2 N protein, were significantly higher among the vaccinated patients (73.8%) as compared to non-vaccinated patients (57.1%), with p = 0.02. There was a downward trend in levels of IgG against the SARS-CoV-2 N protein with increasing age, except for the 60–69 age group.</p>
</abstract>

The spread of SARS-CoV-2 represented a global health crisis. On May 5, 2023, the chief of the World Health Organization (WHO) officially announced the end of COVID-19 as a global health emergency. Serological assays can identify previously infected SARS-CoV-2 individuals, even if they did not go for testing while acutely ill. The current study sought to detect antibodies directed against the nucleocapsid of SARS-CoV-2 (IgG against the SARS-CoV-2 N protein) in both vaccinated and unvaccinated COVID-19 individuals. Of the 100 participants, 53 and 47 were vaccinated and unvaccinated, respectively. The vaccination status of the cohort based on gender data indicates that 41 (41%) of all participants were vaccinated males, whereas 12 (12%) were vaccinated females. We found that 42 (42%) were unvaccinated males and 5 (5%) were unvaccinated females. Of 53 vaccinated subjects, 42 and 11 participants were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. Of 47 unvaccinated participants, 28 and 19 were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. The average of S/P “Sample/Positive control” percentages, which correlate to levels of IgG against SARS-CoV-2 N protein, were significantly higher among the vaccinated patients (73.8%) as compared to non-vaccinated patients (57.1%), with p = 0.02. There was a downward trend in levels of IgG against the SARS-CoV-2 N protein with increasing age, except for the 60–69 age group.

Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan

Department of Biosciences, Faculty of Science

COMSATS University Islamabad – Islamabad

Institute for Water and Wastewater Technology

Durban University of Technology – Durban

University of Veterinary and Animal Sciences – Lahore

Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences

National University of Science and Technology – Islamabad

Acta Medica Bulgarica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The spread of SARS-CoV-2 represented a global health crisis. On May 5, 2023, the chief of the World Health Organization (WHO) officially announced the end of...

Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan

Publié en ligne: 16 mars 2024

Pages: 30 - 35

Reçu: 29 mai 2023

Accepté: 10 août 2023

DOI: https://doi.org/10.2478/amb-2024-0005

Mots clés
SARS-CoV-2 N protein, COVID-19, SARS-CoV-2

© 2024 A. Donia et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan

Publié en ligne: 16 mars 2024

Pages: 30 - 35

Reçu: 29 mai 2023

Accepté: 10 août 2023

DOI: https://doi.org/10.2478/amb-2024-0005

Mots clésSARS-CoV-2 N protein, COVID-19, SARS-CoV-2

© 2024 A. Donia et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
SARS-CoV-2 N protein, COVID-19, SARS-CoV-2